Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer ...

"Zentalis reported significant progress in the ... Continuing patient enrollment across clinical pipeline. The Company is continuing to enroll patients in its ZN-c3-002 Phase 1b dose escalation ...

“We made excellent progress across our pipeline in 2024 ... He was most recently employed at Zentalis Pharmaceuticals where he played a key role in the strategy and execution of the global ...

"We made excellent progress across our pipeline in 2024, laying a strong foundation for ... He was most recently employed at Zentalis Pharmaceuticals where he played a key role in the strategy and ...

Story Jan. 29 - I-Mab: After announcing a pipeline restructure earlier in the month, I-Mab’s has reduced its workforce by around 27%. Story Jan. 28 - Zentalis Pharmaceuticals: In hopes of ...

“Zentalis reported significant progress in the development ... Together with the other members of the leadership team, the Company refined and sharpened its pipeline. In January 2025, the Company ...

Zentalis and ORIC have also announced their ... MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.

"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...

Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Telecoms, Financials and Oil & Gas sectors ...

DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical ...